TROY, Mich. -- April 4, 2001 -- The first significant, peer-reviewed study of Surgical Anterior Ventricular Restoration, or SAVR, shows that SAVR is an effective treatment for certain types of congestive heart failure, substantially improving survival and hospital admission rates of patients undergoing the procedure, announced Somanetics Corporation (Nasdaq: SMTS).

The study, titled “Surgical Anterior Ventricular Endocardial Restoration (SAVR) in the Dilated Remodeled Ventricle Following Anterior Myocardial Infarction,” was published in the April issue of the Journal of the American College of Cardiology. The study, conducted by an international group of researchers from 11 hospitals, reports the 18-month follow-up results of 439 NYHA Class III and Class IV congestive heart failure patients treated with SAVR.

SAVR candidates evaluated in this study included Class III and Class IV congestive heart failure patients with enlarged, poorly functioning hearts due to a prior heart attack involving the anterior wall of the ventricle. Of the entire heart failure population, an estimated 2 million people worldwide could be candidates for SAVR.
In addition to developing the CorRestore patch, Somanetics manufactures and markets the INVOS® Cerebral Oximeter patient brain oxygen monitoring system, the only noninvasive and continuous monitor of changes in regional oxygen saturation of a patient’s blood in the brain commercially available in the U.S. Use of the patient monitoring system can help medical professionals, such as surgeons and anesthesiologists, identify regional blood oxygen imbalances and take corrective action. Such action can potentially prevent or reduce neurological injuries related to adverse events during surgery or in the critical care unit and reduce the associated cost of care.

Except for historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements. Actual results may be affected by, among other things, risks and uncertainties related to the ability to raise adequate capital to sustain operations, new product development cycles, the costs of developing the CorRestore patch and the time to reach market, the demand for and market for products in domestic and international markets, economic conditions in general and in the healthcare market, research and development activities, regulatory approvals of new products, introduction of competitive products by others, third party reimbursement, physician training, and other factors set forth from time to time in Somanetics’ Securities and Exchange Commission filings, including Somanetics’ Registration Statement on Form S-1 (file no. 333-33262) effective March 31, 2000.

###